Análisis de la acción Vivos Therapeutics Inc (VVOS)VVOSVivos Therapeutics Inc

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Vivos Therapeutics Inc (VVOS) is currently not a strong buy due to its high volatility and substantial losses. The stock is trading at $0.13, down 94.72% year-to-date, and has a low RSI of 39.57, indicating potential weakness. While the company reported a 35% year-over-year revenue increase to $5.2 million in Q2 2026, the net loss widened to $5.5 million, highlighting ongoing financial challenges. The main risk is the company's cash position, with only $1.8 million available, insufficient to fund operations for the next 12 months, which could lead to further dilution or financial distress.